Placebo FDC

DRUG2 trials

Sponsors

Actelion, Janssen Research & Development, LLC

Conditions

Metastatic Castration-sensitive Prostate CancerPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Phase 3

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

CompletedNCT03904693

ActelionPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Start: 2019-07-29End: 2024-09-27Updated: 2025-12-19

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Active, not recruitingNCT04497844

Janssen Research & Development, LLCMetastatic Castration-sensitive Prostate Cancer

Start: 2020-09-23End: 2027-11-01Updated: 2026-08-20

Related Papers

Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label Period

Advances in Therapy2026-03-12

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

2025-10-072 citations

Macitentan Plus Tadalafil Single-Tablet Combination Therapy in Chinese Patients With Pulmonary Arterial Hypertension: A Subgroup Analysis of the A DUE Study.

2025-10-01

Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.

Journal of Clinical Oncology2025-06-0413 citations

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

2025-03-074 citations

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.

2024-01-0137 citations

Genetic Landscape of Advanced Prostate Cancer Explored

Oncology Times2023-12-051 citations

Macitentan tadalafil fixed dose combination (FDC) in patients with pulmonary arterial hypertension (PAH): A subgroup analysis from A DUE

2023-09-09

AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology2021-02-2044 citations